Evidence Hub

Remission of bulimia nervosa observed during administration of liraglutide and metformin: a case report

Margarita Perez-Cheron

2017

5 citations

Abstract

Objective: Bulimia nervosa, an eating disorder characterized by recurrent binging and purging episodes, is frequently associated with depression. Conventional therapy with antidepressants and cognitive behavioral therapy has poor long-term success. Appetite-regulating gut hormones such as glucagon-like peptide 1 (GLP-1) may be implicated in the pathophysiology, and thus, GLP-1 receptor agonists may be an effective therapy. Methods: A 26-year-old patient with polycystic ovary syndrome (PCOS) on chronic metformin therapy, with reactive hypoglycemia, bulimia nervosa, and depression, unresponsive to antidepressants and psychotherapy, was given a trial of liraglutide 1.2 mg daily to control hunger and prolong satiety. Results: The patient reported a more prolonged sensation of satiety after meals and complete resolution of her bulimic behavior within 2 weeks of starting liraglutide. She remains 5 years later with absence of bulimic behavior. She has tried stopping metformin or liraglutide separately but notice...

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free